BioSphere Medical, Inc. Announces New Corporate Web Site.

MARLBOROUGH, Mass.--(BW HealthWire)--Nov. 16, 1999--

BioSphere Medical, Inc. (OTCBB: BSMD), a medical device company that is pioneering the use of patented and proprietary bioengineered micropheres in embolotherapy, announced today that it has formally launched a new corporate Web site (www.biospheremed.com). The site provides information on the Company, its products and its markets. The site also includes pertinent clinical data for physicians.

"Our new site reflects BioSphere Medical's mission as a newly formed company and our prospects in the rapidly expanding embolotherapy market," stated BioSphere Medical President and Chief Executive Officer John Carnuccio. "With its depth and breadth of easily accessible product and investor information, the site is also an example of our ongoing commitment to our stockholders, customers and employees."

Biosphere Medical filed a FDA 510(k) application for Embosphere(R) Microspheres in May 1999 to treat hypervascularized tumors and arteriovenous malformations, and expects to launch the product early next year. Further, an IDE application for use of Embosphere Microspheres in uterine artery embolization (UAE) has been approved by the FDA and clinical trials will begin by the end of this year. UAE is the occlusion of the blood supply to uterine fibroids to reduce their size and alleviate associated symptoms, including pain, bleeding and disfigurement.

BioSphere Medical, Inc., based in Marlborough, Massachusetts, is a medical device company focused on embolotherapy, the treatment of tumors and vascular disease by inhibiting blood flow. The Company is pioneering the use of bio-engineered microspheres as a new class of embolic devices.

This press release contains forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual events to differ materially from those indicated by forward-looking statements in this release are the failure of the Company to achieve or maintain necessary regulatory approvals, either in the United States or internationally, with respect to the manufacture and sale of its products; to successfully develop and commercialize the Embosphere(R) Microspheres technology for Uterine Artery Embolization and other applications; to provide patent and other proprietary protection for the Company's products and to garner the necessary U.S. regulatory approvals for such technology; the absence of, or delays and cancellations of, product orders; the delay in the introduction of new products; competitive pressures; the inability of the Company to raise additional funds, if needed, to finance the development, marketing, and sales of its products; general economic conditions; as well as those risk factors detailed in the periodic reports filed by the Company with the Securities and Exchange Commission.